Lineage Cell Therapeutics financials
$0.9475−2.42%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.1M | $1.7M | $6.6M | $3.7M | $2.8M | $1.5M | $2.9M | $3.8M | $1.4M | $1.4M | $2.1M | $1.2M |
| Gross profit | $1.1M | $1.7M | $6.6M | $3.7M | $2.8M | $1.5M | $2.9M | $3.8M | $1.4M | $1.3M | $1.8M | $1.1M |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 93.2% | 87.7% | 86.4% |
| Operating income | -$8.9M | -$7.6M | -$6.5M | -$3.8M | -$19.8M | -$6.5M | -$5.1M | -$3.8M | -$5.9M | -$6.7M | -$6.4M | -$6.7M |
| Net income | $1.5M | -$4.8M | $851.0K | -$29.8M | -$30.5M | -$4.1M | -$3.3M | -$3.0M | -$5.8M | -$6.5M | -$4.8M | -$7.1M |
| Net margin | 138.6% | −279.0% | 12.9% | −809.0% | −1101.8% | −275.6% | −114.1% | −80.3% | −409.1% | −453.0% | −228.7% | −570.6% |
| Diluted EPS | $-0.03 | $-0.03 | $0.00 | $-0.13 | $-0.13 | $-0.02 | $-0.01 | $-0.02 | $-0.03 | $-0.04 | $-0.03 | $-0.04 |
| EBITDA | -$8.7M | -$7.4M | -$6.4M | -$3.6M | -$4.8M | -$6.3M | -$5.0M | -$3.7M | -$5.7M | -$6.5M | -$6.2M | -$6.5M |
| Operating cash flow | -$7.2M | -$8.1M | -$4.9M | -$3.6M | -$5.5M | -$4.9M | -$6.3M | -$5.8M | -$5.2M | -$5.8M | -$6.0M | -$5.0M |
| Free cash flow | -$7.4M | -$8.1M | -$5.3M | -$3.6M | -$5.6M | -$5.0M | -$6.7M | -$5.9M | -$5.2M | -$5.8M | -$6.1M | -$5.2M |
| Diluted shares | 261.5M | 261.2M | 237.2M | 228.9M | 228.4M | 226.1M | 240.2M | 188.8M | 188.8M | 182.9M | 175.1M | 174.9M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $37.4M | $35.9M | $40.8M | $40.5M | $42.3M | $47.9M |
| Short-term investments | $13.5M | $17.4M | $15.0M | $23.0K | $17.0K | $19.0K |
| Total debt | $48.0K | $54.0K | $69.0K | $83.0K | $98.0K | $107.0K |
| Total assets | $106.2M | $109.5M | $112.6M | $89.6M | $90.8M | $111.8M |
| Total liabilities | $46.4M | $56.8M | $69.2M | $68.8M | $43.7M | $34.1M |
| Shareholders' equity | $59.8M | $52.7M | $43.3M | $20.8M | $47.1M | $77.7M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology